EGFR exon 18 mutation
|
NSCLC
|
EGFR exon 18 mutation
|
NSCLC
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
EGFR exon 18 mutation
|
NSCLC
|
EGFR exon 18 mutation
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR exon 18 mutation
|
NSCLC
|
EGFR exon 18 mutation
|
NSCLC
|
bevacizumab + erlotinib Sensitive: C3 – Early Trials
|
bevacizumab + erlotinib Sensitive: C3 – Early Trials
|
EGFR exon 18 mutation
|
NSCLC
|
EGFR exon 18 mutation
|
NSCLC
|
neratinib Sensitive: C3 – Early Trials
|
neratinib Sensitive: C3 – Early Trials
|
EGFR exon 18 mutation
|
NSCLC
|
EGFR exon 18 mutation
|
NSCLC
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR exon 18 mutation
|
NSCLC
|
EGFR exon 18 mutation
|
NSCLC
|
FCN-411 Sensitive: C3 – Early Trials
|
FCN-411 Sensitive: C3 – Early Trials
|
EGFR exon 18 mutation
|
LUAD
|
EGFR exon 18 mutation
|
LUAD
|
bevacizumab + afatinib Sensitive: C4 – Case Studies
|
bevacizumab + afatinib Sensitive: C4 – Case Studies
|